Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall
C B
CB
Molecular Immunology Department, Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, WA 98121, USA.
D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005098:Exotoxins / Q000494:pharmacology* / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C089583:BR96 sFv-PE40; D005098:Exotoxins; D006023:Glycoproteins; C101006:HAR-TX beta 2 protein, recombinant; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins